FOXO4-DRI vs Spermidine
A side-by-side research comparison of FOXO4-DRI and Spermidine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FOXO4-DRI | Spermidine |
|---|---|---|
| Full name | FOXO4-D-Retro-Inverso Peptide (Senolytic) | Spermidine (Polyamine) |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | Dietary compound (research ongoing) |
| Mechanism | Competitively disrupts FOXO4 sequestration of p53 in senescent cells, releasing p53 to trigger intrinsic apoptosis selectively in cells relying on this survival mechanism. | Induces autophagy, partly by inhibiting acetyltransferase activity and mimicking caloric restriction signaling. This promotes clearance of damaged proteins and organelles, supporting cellular renewal, cardiovascular health, and cognition. |
| Molecular weight | ~4,500 Da | 145.25 Da |
| Half-life | 12-24 hours (D-amino acid stability) | Short; rapidly absorbed and distributed |
| Bioavailability | Moderate (SubQ) | Oral absorption reported; also produced by gut bacteria |
| Typical dose | 5-10 mg/kg (animal studies) | 1-10 mg per day |
| Frequency | 3x per week for 3 weeks | Once daily |
| Route | Subcutaneous | Oral |
FOXO4-DRI reported benefits
- Selective senescent cell elimination
- Potential aging reversal
- Improved tissue function
- Reduced inflammatory burden
- Hair regrowth (mice)
Spermidine reported benefits
- Induces autophagy (cellular clean-up)
- Cardiovascular support
- Cognitive and memory support (research)
- May support hair and overall longevity
Related comparisons
Research and educational reference only. Not medical advice.